SCHEMBL5317712

SCHEMBL5317712

O=c1[nH]c(=S)ccn1[C@H]1C[C@H](O)[C@@H](COP(=O)(O)O)O1

nearest known ligand 0.64

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ DUT P33316 1/20 0.63
▸ TYMS P04818 6/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7064249 1.00 DUT (0.63) DUTTYMS
SCHEMBL15810769 0.90 P2RY2 (0.66) DUT
Deoxyuridine Monophosphate SCHEMBL25024676 0.89 DUT (0.77) DUTTYMS
Deoxyuridine Monophosphate SCHEMBL8200 0.89 DUT (0.77) DUTTYMS
Deoxyuridine Monophosphate SCHEMBL888328 0.89 DUT (0.77) DUTTYMS
Deoxyuridine Monophosphate SCHEMBL21941035 0.89 DUT (0.77) DUTTYMS
Deoxyuridine Monophosphate SCHEMBL9830961 0.85 DUT (0.72) DUTTYMS
SCHEMBL28552817 0.83 TK1 (0.59) —
SCHEMBL8338549 0.83 TK1 (0.59) —
SCHEMBL440592 0.83 TK1 (0.59) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007083173-A2 MONONUCLEOTIDES AND MONONUCLEOSIDES FOR USE IN THERAPY UNIVERSITY OF DEBRECEN (HU) 2007-07-26 — — WO disclosed
US-20030216334-A1 Methods for inhibiting/treating hiv infections and aids related symptoms THEREX TECHNOLOGIES, INC. 2003-11-20 — — US disclosed
US-20030216334-A1 Methods for inhibiting/treating hiv infections and aids related symptoms THEREX TECHNOLOGIES, INC. 2003-11-20 — — US disclosed
EP-1248631-A1 METHODS FOR INHIBITING/TREATING HIV INFECTIONS AND AIDS RELATED SYMPTOMS Therex Technologies, Inc. (US) 2002-10-16 — — EP disclosed
EP-1248631-A1 METHODS FOR INHIBITING/TREATING HIV INFECTIONS AND AIDS RELATED SYMPTOMS Therex Technologies, Inc. (US) 2002-10-16 — — EP disclosed
WO-2001049297-A8 METHODS FOR INHIBITING/TREATING HIV INFECTIONS AND AIDS RELATED SYMPTOMS THEREX TECHNOLOGIES INC (US) 2002-02-07 — — WO disclosed
WO-2001049297-A1 METHODS FOR INHIBITING/TREATING HIV INFECTIONS AND AIDS RELATED SYMPTOMS THEREX TECHNOLOGIES, INC. (US) 2001-07-12 — — WO disclosed
WO-2001049297-A1 METHODS FOR INHIBITING/TREATING HIV INFECTIONS AND AIDS RELATED SYMPTOMS THEREX TECHNOLOGIES, INC. (US) 2001-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216334-A1 Methods for inhibiting/treating hiv infections and aids related symptoms DUT, SAMHD1, TYMP DUT 1/4885TYMS 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback